

Table 2. Additional Guidance on the Management of Rheumatic and Musculoskeletal Disorders During the COVID-19 Pandemic

Guideline	Comment
European League Against Rheumatism (EULAR)¹¹	Provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Provides 5 overarching principles and 13 recommendations addressing: <ul style="list-style-type: none"> • Prevention of SARS-CoV-2 infection • Management of rheumatic and musculoskeletal disorders when local measures of social distancing are in effect • Management of COVID-19 in the context of rheumatic and musculoskeletal disorders • Prevention of infection other than COVID-19
Asia Pacific League of Associations for Rheumatology (APLAR)²²	A position statement on the care of patients with rheumatic diseases during the COVID-19 pandemic provides general guidance on the use of various therapies including: <ul style="list-style-type: none"> • NSAIDs • Glucocorticoid therapy • Conventional synthetic and biologic disease-modifying anti-rheumatic drugs
The French Society of Rheumatology²³	Provides answers to most frequently asked questions in managing patients with rheumatic diseases during the COVID-19 pandemic, based on the evidence up to May 2020, including: <ul style="list-style-type: none"> • Can local joint injections be carried out? • Can biologic therapies be used? • Should consideration be given to switching biologic from intravenous to a subcutaneous administration? • For patients undergoing parenteral treatment (eg, methotrexate, teriparatide, denosumab), should another route of administration or alternative therapy be considered? • When should background therapy be resumed following recovery from COVID-19 infection?
British Society of Rheumatology²⁴	Guides physicians and patients on managing rheumatic and musculoskeletal diseases during the COVID-19 pandemic, including: <ul style="list-style-type: none"> • Options to start or escalate rheumatic and musculoskeletal disease treatment • Frequency of blood testing • Risk stratification guide for identifying patients for shielding